Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case Series - PubMed
6 hours ago
- #Antiretroviral therapy
- #Dolutegravir
- #HIV/TB co-infection
- Study evaluates efficacy of Dolutegravir plus Lamivudine (DTG + 3TC) in TB/HIV co-infected patients on rifampicin or rifabutin-based regimens.
- 42 out of 46 TB/HIV co-infected patients were enrolled in a retrospective observational case series from 2021 to 2023.
- All patients achieved successful TB treatment and 100% viral suppression (VL < 50 copies/mL) from a baseline VL > 500,000 copies/mL.
- 73.8% of patients on rifabutin-based anti-TB regimen achieved viral suppression by week 24.
- Significant improvement in CD4 + T-cell counts and CD4 + /CD8+ ratio (increase by 0.38, p < 0.001).
- No serious adverse events were observed, and lipid profiles remained stable except for total cholesterol and HDL (p < 0.05).
- Study preliminarily validates efficacy of DTG + 3TC with rifabutin-based anti-TB regimens in TB/HIV patients.